Berry Consultants Acquires 100% Interest in Clinical Trial Simulation Software

Full Control of Software allows for continued expansion of the tool and enhances their Adaptive Clinical Trial Design Services

AUSTIN, Texas--()--Berry Consultants, LLC announced today that it has reached an agreement with Tessella to acquire 100% ownership of FACTS. Previously, FACTS was jointly developed and owned by Berry Consultants and Tessella, but this agreement gives Berry Consultants full ownership of the software. FACTS (Fixed and Adaptive Clinical Trial Simulator) is the most powerful, versatile, and fastest clinical trial simulation tool on the market today. FACTS allows biostatisticians and clinical teams to rapidly design and compare innovative, advanced, clinical trial designs. As part of the agreement, Tessella will remain as an IT service contractor of Berry Consultants providing support and transitional assistance as needed.

“FACTS is a powerful tool for the clinical trial industry today, but even more looking forward,” said Dr. Scott Berry, President of Berry Consultants. “We believe in the future all clinical trials will require the type of detailed, complex, simulations that FACTS provides -- it is the flight simulator of a clinical trial. It allows trials to be run millions of times before the actual trial—to think through all the possibilities and outcomes before they occur. We appreciate Tessella’s partnership, support, and expertise in developing FACTS. It is the natural progression and growth of Berry Consultants to expand and develop FACTS going forward.”

Tessella’s Life Sciences Director, Dr. Alan Bell, said, “Pharmaceutical and Biotech companies’ use of analytics and analytical tools to improve efficiency and effectiveness will continue to grow. The success of FACTS confirms this and also Tessella’s ability to deliver complex analytics projects and programmes that need robust, powerful and sophisticated software systems which are easy to use.” Dr. Bell added, “We are excited by Berry Consultants’ plans to develop FACTS further and look forward to working with them to smoothly and seamlessly transition support, project management and software engineering responsibilities over the next three years. We will continue to work with Berry Consultants supporting the execution of adaptive clinical trials.”

About Berry Consultants

Berry Consultants is a statistical consulting company specializing in the Bayesian approach to medical statistics, an approach that is radically changing the way research is done throughout both device and drug development. Berry Consultants employs world-renowned experts in Bayesian statistics and strives to set the standard for innovative clinical trial design and analysis in the statistical and medical communities. www.berryconsultants.com

About Tessella

Tessella is an international analytics, software services and consulting company known for finding and delivering innovative answers to the complex business and technical challenges of some of the world’s most forward-thinking organisations. We are innovative problem solvers, passionate about science and technology, committed to excellence, and to our clients’ success. Our work includes some of the most exciting and ambitious projects of our time. These projects make the world a better place: increasing productivity in the development of new medicines; designing satellites to observe and understand our universe; harnessing fusion power to provide unlimited, clean energy; minimising risk for workers in harsh and dangerous conditions; and protecting the digital heritage of nations. www.tessella.com

Contacts

Berry Consultants
Shawn Andersson, 512-213-2277
shawn@berryconsultants.com
or
Tessella
Christina Tealdi, +44 (0) 1235 546 638
pressoffice@tessella.com

Release Summary

Berry Consultants acquires 100% interest in clinical trial simulation software -- FACTS (Fixed and Adaptive Clinical Trial Simulator).

Contacts

Berry Consultants
Shawn Andersson, 512-213-2277
shawn@berryconsultants.com
or
Tessella
Christina Tealdi, +44 (0) 1235 546 638
pressoffice@tessella.com